G-band and rapid FISH/QF-PCR are regarded as the gold standards for prenatal chromosomal diagnosis. Numerous microdeletion/ microduplication syndromes, however, are not detectable by conventional karyotyping. So far, we had a dilemma between fetal developmental/structural abnormalities with strong suspicion of chromosomal abnormalities and normal karyotype results. Fetal DNA chip includes more than 6,450 genetic loci and covers more than 100 common genetic diseases with numeric, structural chromosomal anomalies.
INTRODUCTION
Recent advances of fetal imaging technology have been remarkable, and prenatal detection and diagnoses have been shifted from the second and third trimesters to the first trimester. However, we still have dilemma in fetal diagnoses of normal karyotype cases with strong suspicion due to sonographic abnormalities.
G-band and rapid FISH/QF-PCR are regarded as the gold standards for prenatal chromosomal diagnosis. Numerous microdeletion/microduplication syndromes, however, are not detectable by conventional karyotyping. The latest development in microarrays enables the detection of submicroscopic deletions/duplications. Relevance of genetic alteration in developmental and behavioral etiology remains to be determined. A number of genetic and environmental factors are taken into account as responsible for congenital structural abnormalities, intrauterine growth restriction and organ developmental delay.
Array-comparative genomic hybridization (aCGH) was developed as a high-resolution analysis of DNA copy number variations, initially in cancer studies, and subsequently extended to postnatal evaluation of mental retardation and multiple congenital anomalies. Array-CGH offers a rapid analysis of the DNA copy number variations with results of a comprehensive genome-wide picture available within 3 days' time, much shorter than the G-banded analysis, which takes at least 2 weeks. In addition, its superior resolution allows detection of submicroscopic microdeletions or microduplications, and a more precise delineation of chromosomal aberrations leading to improved genotype-phenotype correlation. However, aCGH cannot detect truly balanced chromosomal rearrangements or polypoidy, and may even generate data with unknown significance. Knowing its limitations and with proper counseling of the advantages and shortcomings, aCGH will become the first-line diagnostic test for management of pregnancy with fetal sonographic anomalies.
Submicroscopic microdeletions and microduplications have been reported to be associated with developmental and behavioral abnormalities. 1 Thus, aCGH increased the ability to detect segmental genomic copy number variations in patients with global developmental delay, mental retardation, autism, multiple congenital anomalies and dysmorphism, and is becoming a powerful tool in disease gene discovery and prenatal diagnostics. 2 Clinical investigation using aCGH in the field of prenatal diagnosis has recently introduced, and several reports on relations between fetal abnormalities and abnormal aCGH results have been published. 3, 4 Fetal DNA chip is a specially designed diagnostic chip to interrogate over 100 recognized genetic syndromes plus every region known to be involved in cytogenetic abnormalities with 50-fold-higher-resolution than conventional karyotyping. Exam duration of fetal DNA chip is quite fast (2-4 days, at longest 7 days from sampling). Fetal DNA chip v1.0. The aim of fetal DNA chip is to diagnose both common and less common, but clinically significant, cytogenetic aneusomies, including microdeletion/microduplication. Its average genome wide resolution is 100 kb. Fetal DNA chip includes more than 6,450 genetic loci and covers more than 100 common genetic diseases with numeric, structural chromosomal anomalies. In April 2009, we launched prenatal diagnosis by fetal DNA chip of amniotic fluid samples or chorionic villi samples in the selected fetuses with sonographic abnormalities and suspicion of familial genetic disorders.
Sonographic Abnormalities with Pathologic Copy Number Variations
Patients and methods: Seven cases with sonographic abnormalities suspected as an abnormal karyotyping, but not common aneuploidy, were selected. Immediately after confirming negative QF-PCR result of chromosomes 13, 18, 21, X and Y on the next day of sampling, fetal DNA chip ( Fig. 1) (Figs 5A to C) . In all cases, normal karyotype was confirmed by G-banding analysis.
DISCUSSION
The advantages of fetal DNA chip comparing to conventional chromosomal analysis of karyotyping are as below.
•
Fetal development and structural abnormality may be strongly related to chromosomal aberration. So far, we had a dilemma between fetal developmental and structural abnormalities with strong suspicion of chromosomal abnormalities and normal karyotype results. Fetal DNA chip (aCGH) may become a strong modality to solve some part of this dilemma. The introduction of microarray analysis has provided considerable benefit to clinical practice, compared to traditional approaches. Most importantly, it has enabled specific diagnoses to be made in a number of patients with subsequent benefits to the family in terms of the provision of accurate prognostic information and recurrence risk counseling.
Cytogenetic studies have demonstrated that duplications or deletions of entire chromosomes or microscopically visible aberrations are associated with specific congenital disorders. 
DSJUOG
Pathogenic CNVs are associated not only with birth defects and cancers but also with neurodevelopmental disorders at birth or neurodegenerative diseases in adulthood. Unfortunately, the limited knowledge of the phenotypic effects of most CNVs has led to the classification of many CNVs as genomic imbalances of unknown clinical significance. This has caused many clinicians to resist the introduction of microarray technologies in detecting CNVs in a genome-wide manner for prenatal applications. 6 Where the microarray result is normal, exclusion of a chromosomal etiology allows the clinician to shift the diagnostic focus onto other etiologies, such as Mendelian disorders and environmental insults. 5 The subsequent development and application of microarray-based assays have established the importance of copy number variants (CNVs) as a substantial source of genetic diversity in the human genome. 6 However, array-CGH is not an accomplished modality. Furthermore, interpretation of microarray data is complicated by the presence of both novel and recurrent copy number variants (CNVs) of unknown significance. Many of copy number variations exist, which are uncertain to be associated with abnormal phenotypes or to be considered as normal variations, and there should be more normal variations not reported yet. Evidence-based classification of pathogenic or benign status of a CNV in clinical genetics 7 is required. 
